Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

Background This randomised study was designed to determine the response rate, survival and toxicity of single-agent gemcitabine and cisplatin-etoposide in chemo-naïve patients with locally advanced or metastatic non-small-cell lung cancer. Patients and methods Gemcitabine 1,000 mg/m2 was given as a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 1997-06, Vol.8 (6), p.525-529
Hauptverfasser:	Manegold, C., Bergman, B., Chemaissani, A., Dornoff, W., Drings, P., Kellokumpu-Lehtinen, P., Liippo, K., Mattson, K., Pawel, J. v., Ricci, S., Sederholm, C., Stahel, R. A., Wagenius, G., Walree, N. v., ten Bokkel-Huinink, W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy cisplatin Cisplatin - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use etoposide Etoposide - administration & dosage Female gemcitabine Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Neoplasm Metastasis non-small-cell lung cancer Pharmacology. Drug treatments randomised phase II study
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!